There are different opinions among the expert community about what should be a priority in the formation of restrictive lists of drugs. A retrospective compliance analysis of the structure of the Russian restrictive drug lists with the Global Burden of Disease was conducted. As a result, the strategy of forming restrictive lists of medicines on the priorities of the Global Burden of Disease (mortality, DALY) - is the right way, and this trend is clearly visible in most areas. A high proportion of high-cost oncological and orphan drugs was found in the restrictive lists of drugs, and it is necessary to develop additional criteria for making decisions about inclusion, perhaps, managed entry agreements.